Tamarind seeds join the fight against dry eye

Article

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Tamarind seed polysaccharide (TSP) 0.5% and 1% offers at least equivalent relief from dry eye symptoms as hyaluronic acid (HA), according to a study published online by BMC Ophthalmology in March.

Maurizio Rolando and Cristiana Valente from the University of Genoa, Italy compared the activity of TSP and HA in an open-label, randomized, single centre clinical study. Thirty subjects were randomized to receive three or more applications per day of either TSP 0.5%, TSP 1% or HA 0.2% over a 90 day period. Tolerability was assessed by visual analogue scale (VAS).

TSP 0.5% and 1% were comparable to HA in terms of tolerability, stability of the pre-corneal tear film and corneal and conjunctival staining. However, TSP was found to be more beneficial than HA in terms of addressing subjective symptoms such as trouble blinking, ocular burning and foreign body sensation.

It was concluded that TSP is at least as effective against dry eye as HA and the authors suggest that larger studies are required to further establish the efficacy and safety of the compound as a treatment for dry eye syndrome.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.